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R. Paul Robertson, MD 
Editor-in-Chief 
The Journal of Clinical Endocrinology & Metabolism 
Dr. Robertson, 
 
We are delighted to have received such positive reviews for our manuscript, # JC-15-2873; 
"Female Reproductive Disorders, Diseases & Costs of Exposure to Endocrine Disrupting 
Chemicals in the European Union."  In an accompanying document, you will find responses in 
italics to each point raised. Together these modifications have served to greatly improve the 
manuscript.   
 
We look forward to further communication and final acceptance for publication. 
 
Sincerely, 
 
Leonardo Trasande, MD, MPP on behalf of the coauthors 
 
Cover Letter
Reviewer #1: Hunt et al, Female Reproductive Disorders, Diseases & Costs of Exposure to 
Endocrine Disrupting Chemicals in the European Union 
This MS is part of a series on EDS, disease and costs of exposure (4 articles in the April 2014 
issue of this journal). Like the already published articles, it contains very valuable information 
about the economic burden of disease attributable to ADULT exposure to EDS.  
This is a clearly written article. Although the readership of this journal presumably is mainly 
clinical endocrinologists, this reviewer suggests giving a brief description of the known modes of 
action of DDE and phthalates (the first time the word mechanism appears is on page 18 and is 
unreferenced). 
Additionally or alternatively, given that binding to receptors is just one of the modes of action, it 
would be good to add one or two paragraphs on animal toxicology on the evidence that these 
chemicals produce comparable results in rodents and humans. The authors have indicated that 
the effects of DES in humans and animals are highly similar. Could this be stated about DDE and 
phthalates with regard to the end points covered by this MS? 
This reviewer is correct - an important chunk was missing from the originally submitted version.  
However, because it is an extremely sizeable chunk, we chose to address it by inserting a brief 
summary of and reference to the Endocrine Society’s most recent review of EDCs. This provides 
– in a single place – the best summary of the available evidence of the reproductive hazards 
posed by EDCs.  The mode of action of these chemicals is complex and, for many reported 
effects, remains incompletely understood.  Thus, we found this difficult to summarize briefly and 
addressed this concern by including a statement regarding mechanism of action in the 
paragraph summarizing the Endocrine Society statement and referring the reader to a relevant 
table in this document.   
We thank this reviewer for suggesting the inclusion of a bigger picture view at the outset, it 
strengthens the paper. 
 
 
 
 
This reviewer's comments are given as a suggestion to improve the manuscript. It is entirely up 
to the authors to decide whether or not to follow this advice. 
 
Reviewer #2:  
This manuscript describes the review of numerous papers demonstrating links between endocrine 
disruptor exposure and latent female reproductive disease and has linked this potential causality 
Rebuttal
to the cost burden of the chosen disease end points in the EU. This approach was interesting and 
eye-opening. Although I had few disagreements with the choice of papers, the reason for 
focusing on the chosen studies, or the resources that were used to assess the cost of disease 
burden, the paper suffered in the clarity in Methods and Results sections. It is not clear if the 
authors just needed to go over the paper once more or if apples and oranges were being 
compared.  
 
Suggested changes:  
Introduction –  
You may want to consider changing the phrase “DES experience”. Something like “human 
prenatal DES exposure paradigm” might be a little more descriptive? 
We have revised as suggested. 
It seems that some important description of DES effects are missing… animals and humans share 
similar malformations of the female repro tract following prenatal DES exposures and the DES-
derived clear cell tumors in women were not mentioned as affecting the female repro tract.  
 
We find this comment puzzling because clear cell adenocarcinoma is mentioned at the onset of 
the DES section.  
 
Methods – 
In organizing this section, is it possible to talk about one disease outcome and then the other? I 
understand why you did it the way it is in the present manuscript, but it really bounced around 
and it moving realted sections together would help focus on the outcome.  
 
We followed the structure of previous papers.  We do sympathize with the reviewer’s concern but 
have not made further changes. 
 
In the data that was used from the DEMOCOPHES study, I feel the need to know if this was data 
from urine (more appropriate than blood) and was there anything unusual about the women in 
this study (infertile, etc)?? 
DEMOCOPHES measurements were in urine and in a general population (now explicated). 
I would like to know more about how sure we should be in the choice of data without having to 
go read the entire paper. We do not have information on other papers that were considered in 
these circumstances, so should have some detail on the “best” paper.  
 
Supplemental tables providing brief information on all papers providing information on exposure 
associations for leiomyoma and endometriosis are included in this revision.   
 
 
In the modeling DDE-fibroids section, “Women in the EU…. ”is too vague. Which women? 
Where is this information coming from? There is no reference. 
This is clarified as follows: “Women in the EU between the ages of 15 and 54 years in the year 2010 were 
assumed to have a distribution of DDE levels corresponding to those identified by Govarts et al.57 and 
divided into percentile ranges on the basis of their DDE measurements (0-9th, 10-24th, 25-49th, 50-74th, 
75-89th, 90-99th).” 
In the same paragraph, for reference 59, give the number of women in the cohort (vs “large 
cohort”). 
This has been added – thank you. 
Same paragraph, more detail is needed for how incidence rates were “obtained”. This sentence is 
not clear. 
We have clarified further. 
Additionally, when you talk about applying these rates to the number of women, it is not clear 
that you have 5 year groupings from the database referenced (#60).  
 
The reference cited has 5-year population data across the lifespan. These were summed as 
appropriate to generate the relevant population data. 
 
Results – 
The results section seems to need another going over. At the end of the first paragraph on pg 14, 
the conclusions sentence is misplaced. The header of the next paragraph is wrong, I believe, and 
the conclusion statement of the first paragraph on page 15 should say POPS maybe, but instead 
says phthalates – the paragraph was all about TCDD and PCBs – and this is confusing as I 
thought it would be about phthalates. This is the only major issue – it was hard to follow all the 
different chemicals discussed when I thought this would be about DDE and fibroids only and 
phthalates and endometriosis. Your tables very clearly state DDE and fibroids and Phthalates and 
endometriosis – results section does NOT match this.  
 
We regret the error, which is now corrected. 
 In the first paragraph of the results, please indicate how many studies were considered. 
The revision addresses this issue through citation.In the second paragraph, first sentence, please 
be clear on which end point these studies were chosen.We have clarified as requested. 
In the bottom paragraph on pg 15, the seven references should be provided in the text - it helps to 
provide those authors with information on whether or not their papers thought to be some of the 
best, as you then clarify why you chose the one paper in the end. It should help them design 
better studies in the future… This long paragraph, which extends to most of page 16, contains no 
references and should have several. Please add in the needed references.  
In response to these comments we have created two supplemental tables that summarize the 
human studies considered in this analysis. Because the experimental evidence is extensive, a 
similar summary is not possible and we have simply referenced the most relevant references in 
the text.   
 
 
The second paragraph on page 16 is not clear enough. Where did the values listed come from?  
We have identified the sample size, and clarified data source for phthalate values. 
There is not enough explanation. What is the age group of the women, again?  
We have clarified the age range as requested. 
 
Discussion –  
You say the “…..exclusion of fetal and peri-conceptional exposures…” in the first paragraph on 
pg 18, when in fact you didn’t exclude the data, there just isn’t any. This needs to be clear.  
 
Thank you  -- revised as requested. 
 
In the second paragraph on pg 19, you again refer to only DDE and phthalate as the focus of this 
assessment. Very confusing based on the comments I provided above – results section does not 
agree with this.  
Also, Table 1 and 2 clearly talk about DDE and Phthalates…..  
 
We have revised as follows: “For reasons of extensive data gaps already outlined, we only quantified 
attributable burden for two classes of EDCs - DDEs and phthalates.” 
 This manuscript is important and I think the comments here will improve future versions of your 
message. 
 
Thanks – these were indeed very helpful. 
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Abstract 
Context: A growing body of evidence suggests that endocrine disrupting compounds (EDCs) 
contribute to female reproductive disorders. 
Objective: To calculate the associated combined health care and economic costs attributable to 
specific EDC exposures within the European Union (EU). 
Design: An expert panel evaluated evidence for probability of causation using the 
Intergovernmental Panel on Climate Change weight-of-evidence characterization. Exposure-
response relationships and reference levels were evaluated, and biomarker data was organized 
from carefully identified studies from the peer-reviewed literature to represent European 
exposure and approximate burden of disease as it occurred in 2010. Cost-of-illness estimation 
utilized multiple peer-reviewed sources. 
Setting, Patients and Participants and Intervention: Cost estimation was carried out from a 
societal perspective, i.e. including direct costs (e.g. treatment costs) and indirect costs such as 
productivity loss. 
Results: The most robust EDC-related data for female reproductive disorders exists for (a) DDE-
attributable fibroids and (b) phthalate-attributable endometriosis in Europe. In both cases the 
strength of epidemiological evidence was rated as low and the toxicological evidence as 
moderate, with an assigned probability of causation of 20-39%. Across the EU, attributable cases 
were estimated to be 56,700 and 145,000 women, respectively, with total combined economic 
and health care costs potentially reaching €163 million and €1.25 billion. 
Conclusions: EDCs (DDE and phthalates) may contribute substantially to the most common 
reproductive disorders in women, endometriosis and fibroids, costing nearly €1.5 billion 
annually. These estimates represent only EDCs for which there were sufficient epidemiologic 
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studies and those with the highest probability of causation.  These public health costs should be 
considered as the EU contemplates regulatory action on EDCs.  
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Introduction 
 
In 2007, Buck Louis and Cooney postulated that environmental factors can impact the 
developing ovary and female reproductive tract, inducing structural and functional changes that 
may manifest as reproductive disorders later in life and predispose women to complex diseases 
such as cancer. This conceptual framework was termed the “Ovarian Dysgenesis Syndrome” 
(ODS; (1, 2), paralleling the testicular dysgenesis syndrome (TDS) which links similar 
interrelated health endpoints across the lifespan in males following peri-conceptional or in utero 
exposures.(3)  
 
The most compelling support for ODS comes from the human diethylstilbestrol (DES) 
experienceexposure paradigm.  DES is a synthetic estrogen prescribed from the 1940s to 1970s 
to pregnant women with ‘high risk’ pregnancies in an attempt to prevent miscarriage. The 
reproductive repercussions of fetal DES exposure became evident when cases of a rare vaginal 
clear cell adenocarcinoma were observed in young DES daughters.(4, 5) Subsequent data from 
nearly 50 years of DES cohort studies provides clear evidence that in utero DES exposure 
increased the incidence of a host of reproductive abnormalities in women, including vaginal 
adenosis, cervical and vaginal hypoplasia, uterine and tubal abnormalities, infertility, early 
menopause, and breast cancer. (6, 7) Some associations are reported for in utero DES exposure 
and the presence of male urogenital abnormalities and complex medical diseases later in 
adulthood(8, 9), although the mechanisms of action are unclear.(10)  
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Importantly, support for the ODS hypothesis also comes from the results of subsequent 
experimental studies in rodents that recapitulated and extended the human findings. For example, 
exposure during pre/peri-natal development is associated with an increased risk of leiomyoma in 
the adult in both DES exposed women (11-13) and mice (14), and with changes in the expression 
of estrogen-responsive genes in adult uterine tissue.(15)  
 
Although the effects of DES exposure on fertility likely result from changes to both the ovary 
and reproductive tract, ovarian effects are difficult to characterize. This is not surprising since 
subtle changes to the developing ovary with or without changes in hormonal signaling can 
manifest as a wide range of phenotypes. These include diminished fecundity (longer time-to-
pregnancy), reproductive impairment (e.g. conception delay or pregnancy loss), infertility, or 
gynecological disorders such as endometriosis, fibroids, premature ovarian insufficiency/failure, 
or polycystic ovarian syndrome (PCOS). Biological plausibility that relatively minor changes in 
the developing ovary has lifelong consequences is demonstrated by the link between maternal 
smoking and reduced fecundity in daughters although effects on the fetal ovary are subtle (16). 
Of added concern are the increasingly reported associations between infertility or gynecological 
disorders and gravid diseases such as type 2 diabetes(17), not to mention later onset adulthood 
diseases. Such examples include a higher risk of autoimmune disorders and cancer for women 
with endometriosis and PCOS, a higher risk of gestational diabetes and metabolic or 
cardiovascular disease among women with PCOS, and a greater risk of cancer among infertile 
women in comparison to unaffected women.(18-25)  
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Although a growing body of evidence exists supporting supports the ODS conceptual paradigm 
and the vulnerability of the developing ovary to the actions of endocrine disrupting chemicals 
(26), characterizing the effects of exposures on the developing ovary remains a formidable 
research challenge. In part, this can be attributed to the “hidden” data problem, the inability to 
observe early reproductive endpoints in females relative to males without invasive procedures. 
Such “hidden” endpoints include some of the earliest gene and sperm related contributions to the 
developing embryo, all of which occur prior to implantation. These early endpoints are well 
suited to investigation in population subgroups, such as couples undergoing assisted reproductive 
technologies and such initiatives are underway for select endocrine disrupting chemicals (EDCs) 
and oocyte maturation or blastocyst formation.(27) However, the ability to link exposures during 
development to ovarian function in adult women remains a critical data gap. 
 
In contrast to the complex ovarian phenotype, effects of environmental exposures on the female 
reproductive tract can manifest as gross structural changes (such as endometriosis and fibroids) 
that are easier to characterize. Together, endometriosis and fibroids represent the most common 
female reproductive disorders with an estimated combined incidence of up to 70% of women 
overall.(28-31) Given their cryptic nature, many women with either endometriosis or fibroids 
remain asymptomatic or undiagnosed and gynecological comorbidity may exist. As such, 
estimating incidences at the population level relies on prevalence estimates largely from women 
seeking clinical care. Nevertheless, an estimated 176 million women worldwide are estimated 
ashave been diagnosed with endometriosis.(32, 33) Among women undergoing surgeries that 
allow for visual diagnosis, endometriosis has been reported in 30%-50% of pelvic surgery 
patients and 4%-43% of tubal sterilization patients, irrespective of presenting signs and 
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symptoms.(34-38) Estimating the incidence of uterine fibroids poses similar problems. Although 
some 20-40% of women of childbearing age are affected, disease incidence is strongly 
influenced by both age and race and, in some populations the lifetime risk may be as high as 
60%.(39, 40)  
 
Because they are leading causes of female infertility and a range of other conditions affecting 
quality of life such as pain(41), these reproductive disorders impose a high personal burden. In 
addition, they also represent a major societal burden, representing a substantial portion of the 
health care costs for women and a leading cause of work disturbances and lost productivity. In 
terms of estimated annual costs per woman in the EU, health and lost productivity together cost 
around €8,000 while hospital costs alone for fibroid treatment average over €3,000.(42-45) 
Furthermore, the rising incidences of endometriosis and fibroids with age(46) increases the risk 
of comorbidity, which will multiply the cost burdens of the diseases. 
 
The Endocrine Society recently released its second Scientific Statement on endocrine disrupting 
chemicals or EDCs.(47) This document reviews the mechanistic, experimental, and 
epidemiological evidence for the role of endocrine disrupting chemicals in the genesis and 
progression of obesity and diabetes, female and male reproductive disorders, hormone-sensitive 
cancers in females, prostate cancer, and developmental and functional disorders of the thyroid 
and neuroendocrine systems.  Importantly, the mode of action of EDCs in the body is varied, 
complex, and dependent upon both the tissue and developmental stage of exposure (e.g., see 
Table 2; ref (47)).  Nevertheless, as summarized in the Endocrine Society statement, evidence for 
effects of a host of EDCs, including bisphenol A (BPA), phthalates, pesticides, and persistent 
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organic pollutants (POPs) on the developing ovary and reproductive tract is growing into a 
compelling body of evidence.   
 
The prevention of EDC exposures has the potential to minimize the onset and progression of 
female reproductive diseases in the EU, and the resultant reduction in associated health care and 
other social costs could have major economic implications.  Thus, cost information is essential in 
the context of regulatory decisions.  We therefore extended previous estimates of societal 
cost(48-51), examining the probability of causation of female reproductive conditions for 
endocrine disrupting chemicals, and quantifying the potential associated costs and burden of 
disease. 
Prevention of EDC exposures minimize the onset of female reproductive diseases in the EU, 
reducing associated health care and other social costs. In the context of the ongoing regulatory 
process in the EU, we therefore examined the probability of causation of female reproductive 
conditions for endocrine disrupting chemicals, and quantified the potential burden of disease and 
associated costs. 
 
Methods 
 
The expert panel focused on two exposure-outcome relationships: adult diphenyldichloroethene 
(DDE) exposure with fibroids and adult phthalate exposure with endometriosis.  The expert 
panel considered dioxins, polychlorinated biphenyls and other persistent pollutants, but 
following the approach of other manuscripts in this series, (48-55) the panel chose not to 
examine these chemicals because  they are already regulated under the Stockholm Convention. 
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The panel selected these exposure-outcome relationships because of the availability of well-
conducted observational human studies to assess effects of these EDCs on female reproductive 
disorders.  The panel recognized that substantial laboratory studies suggest effects of earlier 
female reproductive tract perturbations as a result of developmental exposures in animal(56), but 
noted an absence of longitudinal studies to assess such effects in humans. We adhered to the 
approach described in the accompanying overarching manuscript in evaluating strength of the 
epidemiological (using the WHO GRADE Working Group criteria)(57, 58) and toxicological 
literature (using criteria consistent with that proposed in the European Union roadmap for 
evaluating endocrine disruptors)(59, 60), and to assigning probability of causation (adapting the 
Intergovernmental Panel on Climate Change criteria).(61)  
 
Modeling DDE Exposures among Adult Females in the EU 
 
We utilized data pooled from twelve European birth cohorts by Govarts et al, in which measured 
maternal and cord blood levels of DDE as ng/g.(62) 10th, 25th, 50th, 75th and 90th percentiles in 
cord serum were converted to maternal serum levels using a conversion factor of 0.2:1, as 
described by the authors. For the purpose of this analysis, the distribution of DDE metabolites in 
non-pregnant women in the EU was assumed to match the distributions obtained for pregnant 
women from the pooled European birth cohort data. 
 
Modeling Phthalate Exposures among Adult Females in the EU 
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10th, 25th, 50th, 75th and 90th percentiles for mothers were obtained from the Demonstration of a 
Study to Coordinate and Perform Human Biomonitoring on a European Scale (DEMOCOPHES) 
for the sum of di-2-ethylhexylphthalate metabolites, monoethylphthalate, monoisobutylphthalate, 
monobutylphthalate and monobenzylphthalate in urine from general population samples.(63)  
Molar concentrations were estimated by dividing concentrations in ng/mL by the appropriate 
molecular weight, multiplying by 1000..  For the purpose of this analysis, the distribution of 
phthalate metabolites in women in the EU was assumed to be identical to the distributions 
obtained for mothers from DEMOCOPHES data. 
 
Modeling DDE-attributable Fibroids 
 
Women in the EU between the ages of 15 and 54 years in the year 2010 were assumed to have a 
distribution of DDE levels corresponding to those identified by Govarts et al.57 and divided into 
percentile ranges on the basis of their DDE measurements (0-9th, 10-24th, 25-49th, 50-74th, 75-
89th, 90-99th). The lowest grouping was treated as a reference category, while the other groups 
were assumed to have levels corresponding to the lower value of the interval (e.g., 10th percentile 
for all women in the 10-24th percentile grouping). The panel took the exposure-response 
relationship (ERR) from a study of DDE and fibroids in a large cohort of women undergoing 
laparoscopy or laparotomy for gynecological complaints (n=473) (64). The published odds ratio 
(OR) was applied to the exposure distribution of the population subdivided into 0-9th, 10-24th, 
25-49th, 50-74th, 75-89th, and 90-99th percentiles. Having calculated the appropriate OR for each 
exposed group, the odds ratio was multiplied against the incidence rate surgical/radiological 
interventions for myomas.  , wFor incidence data inputs, we used hich was obtained 
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identifiedincidence rates from an analysis of large national databases from England, Germany 
and France. (42) A population-weighted average of incidence rates from the three countries was 
applied to the other European countries in our study. These rates were applied against population 
estimates of 15-54 year old women in 2010 from Eurostat to estimate the number of DDE-
attributable incident interventions for myomas.(65)  
 
Modeling Phthalate-attributable Endometriosis 
 
The expert panel selected a study of phthalates and endometriosis in population and operative 
cohorts that identified significant associations of DEHP metabolites with endometriosis.(66) For 
the purpose of analysis, women between the ages of 20-44 years in Europe were assumed to have 
urinary phthalate concentrations corresponding to the 10th, 25th, 50th, 75th and 90th percentile of 
adults in the DEMOCOPHES project. The population of 20-44 year old women was divided into 
percentile ranges (0-9th, 10-24th, 25-49th, 50-74th, 75-89th, 90-99th). The lowest grouping was the 
reference category, while the other groups were assumed to have levels corresponding to the 
lowest extreme (e.g., 10th percentile for all women in the 10-24th percentile grouping). ORs were 
calculated by exponentiating the endometriosis OR identified for DEHP metabolites to the ratio 
of the estimated concentration to 0.2 ng/mL. The baseline incidence of endometriosis was 
obtained from a German national analysis(67) and multiplied by the appropriate OR to identify 
the exposed rate of endometriosis. After subtracting the unexposed rate of endometriosis, the 
incremental rate of endometriosis within each group was multiplied by country-level population 
estimates obtained from Eurostat for 20-44 year old women in 2010(65), and the appropriate 
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percentage of the country population corresponding to the percentile range, to estimate 
attributable cases.  
 
Economic Cost Estimates for Fibroids 
 
Costs per case for surgical/radiologic interventions for myomas were identified from an analysis 
of large national databases from England, Germany and France.(42) A population-weighted 
average of costs per case from the three countries was applied to the other European countries in 
our study, after further adjustment by the ratio of each country’s per capita Gross Domestic 
Product to that of Germany, to account for differences in purchasing power across the European 
Union.(68) To update the cost estimates from 2005 to 2010, 4% annual increases in costs per 
case were applied, accounting for well-documented trends across Europe in medical costs.(69)  
 
Economic Cost Estimates for Endometriosis 
 
Costs per patient were adapted from 2009 estimates in Belgium, accounting for direct medical 
costs, as well as lost economic productivity and other indirect costs.(70) Further adjustment was 
made by multiplying the ratio of each country’s per capita Gross Domestic Product to that of 
Belgium, to account for differences in purchasing power across the European Union.(68) To 
update the cost estimates from 2009 to 2010, 4% annual increases in costs per case were applied, 
accounting for well-documented trends across Europe in medical costs.(69)  
 
Results 
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Persistent Organic Pollutant-Attributable Fibroids 
 
The panel considered the evidence supporting a role for both a predisposing effect of 
developmental exposures as well as an effect of adult exposures on the development of fibroids. 
In rodents, DES exposure during fetal development induces alterations to the developing 
reproductive tract that are remarkably similar to those reported in DES daughters.(71) 
Importantly, rodent models also provide evidence that developmental exposures to other EDCs 
induce similar effects.(72-74) Thus, it is important to note that other EDCs, including 
methoxychlor and the persistent organic pollutants (POPs), PCBs and DDT have been implicated 
in the development of uterine fibroid disease.(75-77) These toxicological studies support an 
endocrine disruptor mode of action for adverse health impacts due to chemical exposures. Based 
on these data, the expert panel evaluated the animal/experimental toxicological data supporting 
POP causation of fibroids to be moderate, based upon the limited literature.  
 
In addition to studies of the effects of developmental exposures, we found 11 studies of fibroids 
in adult women that examined a variety of environmental exposures, including phthalates, POPs, 
phenols, trace elements and dietary/lifestyle (Supplementary Table 1).  We found 11 studies of 
adult women that examined a variety of environmental exposures. Of these, 3 focused on 
phthalates, 2 focused on POPs, 1 focused on phenols, and 3 focused on dietary/lifestyle 
factors.(78-84) The body of evidence is observational in nature largely stemming from available 
groups of women for study.  As such, authors used various designs (many cross sectional), 
defined exposures and outcomes differently, and either did or did not consider other covariates.  
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The panel chose the Trabert et al 2014 study for calculations based on: the large sample size 
(N=473) recruited from 14 clinical centers), diagnosis by ultrasonography or at laparoscopy and 
the use appropriate methods for exposure characterization in serum and omental fat for lipophilic 
chemicals. None of the other studies were able to incorporate all of these factors into their study 
design. When excluding women diagnosed with endometriosis, the authors reported several 
PCBs that were significantly associated with an increased risk of fibroids. The ability to quantify 
lipophilic chemicals in omental fat is a strength, as serum concentrations are only proxy of 
internal dose. To our knowledge, no study has been conducted to follow the offspring of women 
whose exposures have been quantified during sensitive windows of development (from 
preconception through adulthood) and in various biologic media that would allow for the 
estimation of the onset and progression of gynecologic disorders including fibroids. Such work 
will be possible in the near future in light of several birth cohort studies with children 
approaching adolescence or young adulthood.  In considering the entire evidence base, the expert 
panel rated the epidemiologic evidence for causation of fibroids by DDE exposure to be low. 
Together, the epidemiological and toxicological evaluations resulted in the expert panel 
endorsing a 20-39% probability of causation of endometriosis fibroids by phthalatesDDE. 
 
Applying the odds ratio (OR) from the Trabert et al 2014 study to DDE biomarker data from 
twelve countries in the EU and using the 10th percentile as a reference level, results in OR 
estimates for fibroids of 1.11-1.51. Applying this to a 2.227/1,000 annual incidence rate, 
incremental prevalence in the EU attributable to DDE ranges between 2.45/10,000 to 1.15/1,000 
for the most highly exposed quantiles of the population (Table 1).  Thus in 2010, an estimated 
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56,700 women underwent interventions for myoma requiring surgical attention attributable to 
adult DDE exposures. These cases cost €163 million. 
 
Persistent Organic Pollutant-Attributable Endometriosis 
 
The panel identified evidence to support the hypothesis that exposures quantified shortly before 
the disease diagnosis are associated with incident disease in women. Experimental evidence 
reflects suggests that following the implantation of human endometrial tissue into the mesentery 
of rats and mice, 12 weeks of TCDD treatment resulted in a significant induction of 
endometriosis in both rodent species.(85) Important primate data also suggests a dose-dependent 
association in both the incidence and severity of endometriosis in a cohort of Rhesus monkeys 
exposed chronically to TCDD.(86) Subsequently, specific PCB congeners (#77 and #126) also 
were associated with endometriosis in this same colony of Rhesus monkeys.(87)  Collectively 
these emerging studies suggest an endocrine disruptor mode of action for TCDD and PCB 
specific congeners leading to the development of endometriosis. Of note, the Rhesus monkey 
experiments were longitudinal in nature and conducted in a primate model that is physiologically 
similar to humans. Therefore, the expert panel felt that these were very high quality experiments 
supporting adverse effects resulting from an endocrine disruptor mode of action from TCDD and 
PCB studies. On the basis of these limited data, the expert panel extrapolated a potential 
endocrine mode of action in animal/experimental toxicological supporting phthalate causation of 
endometriosis to be moderate. 
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Evidence linking classes of environmental chemicals to endometriosis in humans is rapidly 
emerging, with approximately 343 publications examining a variety of chemicals including 
heavy metals, POPs, phthalates, and BPA (Supplementary Table 2). Significant methodological 
limitations (e.g., varying methods of recruitment, disease criteria, methods for detection and 
quantification of analytes, and inadequate statistical power) preclude the use of the majority of 
these studies in evaluating the role of EDCs in the development of endometriosis. Eight of the 34 
publications focused on phthalates as the primary exposure (66, 88-94).  The panel evaluated all 
eight studies; several were rejected due to small sample size, and several others were judged to 
have important methodological limitations, including reliance on self-reported endometriosis 
rather than the gold standard of surgically visualized disease, inappropriate comparison groups, 
or assessment of phthalate exposure occurring after diagnosis. Seven of the 33 publications 
focused on phthalates as the primary exposure and, of these, 3 reported positive results. The 
other four studies were judged to have important methodological limitations, including reliance 
on self-reported endometriosis rather than the gold standard of surgically visualized disease, 
inappropriate comparison groups, and assessment of phthalate exposure occurring after 
diagnosis. The expert panel found the Buck Louis et al. 2013 study to be the most responsive to 
data gaps and other methodological considerations including modern exposure assessment, 
recruitment technique using age and residence matching, direct surgical visualization of outcome 
in operative cohort, and large sample size. In this study, a population based sample of 495 
women undergoing operative evaluation for endometriosis was compared with an age and 
residence matched population sample of 131 women, and six different phthalate metabolites 
were significantly associated with a twofold increase in the odds of endometriosis diagnosis in 
the population cohort. Among women undergoing surgery, mono-octyl phthalate  
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was associated with significantly increased odds ratios of 1.38 (95% CI 1.10, 1.72) based on 
direct surgical visualization and mono 2-ethyl hexyl phthalate 1.35 (95% CI 1.03, 1.78) when 
restricting comparison to women with a normal pelvis. Based on the quality of the adult 
epidemiologic data, the panel assigned the quality of epidemiologic evidence as low based on the 
limited literature and methodological considerations in light of the emerging research in the field. 
These evaluations resulted in the expert panel endorsing a 20-39% probability of causation of 
endometriosis by phthalates. 
 
To estimate attributable disease burden, the panel utilized a large cohort study (n=495) that 
identified a dose-response relationship between urinary phthalate measurements obtained 
contemporaneously with the diagnosis of endometriosis.(66) Applying an odds ratio of 1.35 per 
log unit increase in total phthalates to European urinary total phthalate measurements from 
DEMOCOPHES (Table 2), the incremental incidence attributable to phthalates ranged from 
1.21/1,000 to 2.82/1,000.  In total, this analysis suggests that 145,000 cases of endometriosis 
among 20-44 year old women, with associated costs of €1.25 billion in 2010, were attributable to 
phthalates. 
 
Discussion 
 
The main finding of our study is that EDC exposure may contribute to causation of fibroids and 
endometriosis, with associated costs in the EU of approximately €1.41 billion annually. This 
suggests that prevention of exposures to DDE and phthalates alone would substantially reduce 
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disease and disability among European women, while decreasing health care expenditures and 
other social costs. 
 
We applied a conservative approach to the difficult task of attributing disease burden and costs 
of EDC exposure in the female, focusing on two of the most common female conditions that are 
also amongst the most straightforward in terms of assessing the role of EDCs in etiology.  It is 
important to note that our approach has several limitations that almost certainly result in a 
substantial underestimation of attributing disease burden. First, our analysis focused only on 
adult exposures.  Despite the growing body of experimental data linking EDC exposure during 
fetal development with reproductive aberrations in the adult(95), and aside from the iatrogenic 
effects on offspring of prescribing DES to pregnant women, there are no epidemiological data 
known to us linking fetal exposure to reproductive abnormalities in adult women. Furthermore, 
reliance upon animal model studies is complicated by species-specific differences in biology and 
sensitivity to and/or clearance of EDCs, necessitating careful assessment of animal model 
findings for human relevance. Fetal exposure, however, has the potential to affect reproduction 
by multiple routes (e.g., by interfering with the development of the brain, reproductive tract, and 
ovary), and likely poses the greatest risk to female reproductive health.  Although the 20-30 year 
gap between exposure and the recognition of reproductive impairment (or even longer in terms 
of diagnoses such as premature menopause) presents challenges in establishing etiologic links, 
ongoing birth cohort studies around the globe provide hope for updating the burden of disease 
and cost estimates presented here in the near future.  Nevertheless, the exclusion absence of 
existing studies of fetal and peri-conceptional exposures as which are important windows of 
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exposure prevented inclusion of attribution for these exposures, and represents a major limitation 
of this analysis presented here, one that likely underestimates attributable disease burden.  
 
Second, our analysis only focused on specific reproductive tract disorders. Because 
characterizing the effects of exposures on the developing ovary remains a formidable research 
challenge, the panel elected to focus on two major reproductive tract abnormalities, fibroids and 
endometriosis. While it is highly appropriate to focus on these extremely important uterine tract 
health deficits, PCOS, infertility and pregnancy complications also affect a considerable number 
of women, have major cost implications and are increasingly linked to EDC exposures. Thus, it 
is important to recognize that the cost burdens calculated in this analysis do not represent all – or 
even most – of the reproductive costs associated with human female exposure.  Exposure of the 
mother during gestation can lead to poorer health and function of the offspring, and also will 
have considerable cost implications in terms of maternal stress-induced illness and lost 
productivity due to child-care burdens. Indeed, given the importance of the uterine environment 
and of postnatal maternal care, utilizing disease management costs alone provides an incomplete 
assessment of cost burden. Further, the cost analysis of the two gynecological disorders was 
limited to health care costs and lost work time directly associated with disease treatment, and did 
not take into account the increasingly reported associations between infertility, gynecological 
disorders, gravid diseases, or other later onset adulthood diseases. Important examples include a 
higher risk of autoimmune disorders and cancer for women with endometriosis, a higher risk of 
gestational diabetes and metabolic or cardiovascular disease among women with PCOS, and a 
greater risk of cancer among infertile women in comparison to unaffected women.(18-25)  Thus, 
even this attempt to restrict the analysis of cost burden to two specific reproductive tract 
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disorders must be considered an underestimate of the exposure-associated cost burden from an 
overall health perspective.  
 
Finally, this analysis does not represent the cost to female reproductive health of exposure to all 
EDCs. For reasons of extensive data gaps already outlined, this assessment focused onwe only 
quantified attributable burden for  only two classes of EDCs - DDEs and phthalates. Many other 
EDCs with similar modes of action likely adversely affect female health and function. The 
polycyclic aromatic hydrocarbons represent a large and ubiquitous class of chemicals with 
extensive exposure profiles. These compounds act via an extensive range of mechanisms and 
receptors, including the aryl hydrocarbon and estrogen receptors and have been associated with 
adverse outcomes in offspring(96) and have known effects on reproductive organs.(97) Thus, 
analysis of the burden imposed by exposure only to DDEs and phthalates is a further source of 
potential underestimation of the health burden and cost implications of EDC exposure. 
 
Despite the complexities of the field and the numerous caveats outlined above, the present 
analysis provides some evidence of the health care burden imposed by the two most common 
female reproductive tract disorders -  endometriosis and fibroids. If, as we suggest, our analysis 
provides a conservative estimate that represents the “tip of the iceberg,” the greater than €1.41 
billion per annum cost estimated for the clinical management of two reproductive tract diseases 
associated with exposure to two EDCs suggests that new measures to prevent EDC exposure 
might have considerable personal and economic benefits.  
 
  
 Table 1. DDE-Attributable Fibroids, Europe, 2010. 
       Expert Panel Evaluation of 
Epidemiologic Evidence Low  
Expert Panel Evaluation of Toxicologic 
Evidence Moderate 
Probability of Causation 20-39% 
Percentile of Exposure 0-9 10-24 25-49 50-74 75-89 >90 
Percentile Assumed 0 10 25 50 75 90 
Serum DDE, ng/g 0 473 1000 2236 5000 9414 
Odds Ratio 1.00 1.00 1.11 1.24 1.38 1.51 
Unexposed Incidence 0.00227 
Incremental Incidence 0 0 0.000245 0.000537 0.000864 0.00115 
Attributable Cases 56,700 
Attributable Costs € 163 million 
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Table 2. Endometriosis Attributable to Phthalates in Europe, 2010. 
       Expert Panel Evaluation of 
Epidemiologic Evidence Low  
Expert Panel Evaluation of Toxicologic 
Evidence Moderate 
Probability of Causation 20-39% 
Percentile of Exposure 0-9 10-24 25-49 50-74 75-89 >90 
Percentile Assumed 0 10 25 50 75 90 
Urinary total DEHP metabolites, ng/mL 0 9.70 16.30 29.80 53.20 93.00 
Unexposed Incidence 0.0035 
Incremental Incidence 0 0.00121 0.00154 0.00195 0.00238 0.00282 
Attributable Cases 145,000 
Attributable Costs € 1.25 billion 
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Supplemental Table 1 
Human uterine leiomyoma: Summary of adult association studies  
 
 
Reference 
 
Exposure 
 
Comments 
 
Trabert et al, 
2015(1) 
 
POPs 
 
N= 473 surgical patients 
Association w/ serum levels of several PCBs  
 
Pollack et al, 
2015(2) 
 
BPA 
Phthalates 
UV filters 
 
N= 495 surgical patients 
No significant OR w/ adjustment for relevant 
covariants 
 
Johnstone et al, 
2014(3)  
 
 
Cobalt 
Cadmium 
 
N= 473 surgical patients 
Odds of fibroid dx higher w/ increased serum 
cadmium and lead levels  
 
 
Shen et al, 2013(4) 
Plastics 
Cosmetics 
Food 
additives 
 
Han women in Nanjing, China 
N= 600 with leiomyoma; 600 without 
 
He et al, 2013(5) 
 
Diet 
Physical 
activity 
Stress 
 
 
N= 73 with leiomyoma; 210 without 
 
Wise et al, 2012(6) 
 
Hair relaxer 
 
Women from Black Women’s Health Study 
 
Lambertino et al, 
2011 (7) 
 
POPs 
 
Self reported uternine leiomyoma in women from 
Great Lakes Fish Consumption Study 
 
Huang et al, 
2010(8) 
 
Phthalates 
 
N= 35 with leiomyoma; 29 controls 
Significantly higher urinary MEHP levels than 
controls 
 
Weuve et al, 
2010(9) 
 
Phthalates 
 
N= 151 self-reported leiomyoma in 1999-2004 
NHANES; positive association for MBP, inverse 
association for MEHP 
 
Eskenazi et al, 
2007(10) 
 
POPs 
History of leiomyoma in women from Seveso, Italy 
20 years after chemical explosion and TCDD 
exposure 
 
Luisi et al, 2006(11) 
 
Phthalates 
 
N= 15 with leiomyoma; 20 healthy controls 
Lower serum DEHP, MEHP in women w/ fibroids 
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Human endometriosis: Summary of adult association studies  
 
 
Reference 
 
Exposure 
 
Comments 
 
Pollack et al, 
2015(1) 
 
BPA 
Phthalates 
UV filters 
 
N= 495 surgical patients 
No significant OR w/ adjustment for relevant 
covariants 
 
Pollack et al, 
2013(2) 
 
Trace 
elements 
 
Matched cohort design 
No significant associations 
 
Buck Louis et al, 
2013(3) 
 
BPA 
Phthalates 
 
Population and operative cohorts. Select phthalates 
associated w/ higher odds of endometriosis 
 
Upson et al, 
2013(4) 
 
Pesticides 
 
Case-control study using WREN data 
N=248 endometriosis, 538 controls 
Association with serum βHCH concentrations 
 
Upson et al, 
2013(5) 
 
Phthalates 
 
Population-based case-control study 
Inverse association between urinary MEHP and 
endometriosis 
 
Vichi et al, 2012(6) 
 
PCBs 
 
Case-control study with laprascopic diagnosis 
N=181 endometriosis, 162 controls 
Increased blood levels associated with disease 
 
Trabert et al, 
2010(7) 
 
PCBs 
 
 
Case-control study 
N= 251 surgically confirmed endometriosis, 538 
age matched controls (not confirmed) 
No consistent patterns of risk 
 
Huang et al, 
2010(8) 
 
Phthalates 
 
Case control study 
N=28 endometriosis, 29 controls (surgically 
confirmed) 
Elevated but nonsignificant OR  
 
Weuve et al, 
2010(9) 
 
Phthalates 
 
Cross-sectional study using 1999-2004 NHANES 
Sef-reported diagnosis 
Positive associations for MBP, inverse for MEHP 
 
Cooney et al, 
2010(10) 
 
Pesticides 
 
N=100 patients undergoing laparoscopy 
Increased OR for highest compared to lowest tertile 
for several organochlorine pesticides 
   
Simsa et al, 
2010(11) 
Dioxin-like 
compounds 
Surgical patients; N= 96 endometriosis, 106 control 
Significant odds ratio for women with highest 
plasma concentrations 
 
Porpora et al, 
2009(12) 
 
Dioxin-like 
compounds 
 
Case-control study of laparoscopy patients 
N=80 cases, 78 controls 
Association between increased PCB and p,p'-DDE 
serum concentrations 
 
 
Itoh et al, 2009(13) 
 
Phthalates 
 
Japanese infertility patients 
N=57 endometriosis, 80 controls (laparoscopic dx) 
No significant associations 
 
Niskar et al, 
2009(14) 
 
PCBs 
DDE 
 
Case-control study of laparoscopy patients 
N=90 endometriosis, 34 controls  
No associations 
 
Jackson et al, 
2008(15) 
 
Lead 
Cadmium 
Mercury 
 
Cross sectional study using 1999-2004 NHANES 
data and self-reported endometriosis 
Dose-response association with cadmium 
 
Itoh et al, 2008(16) 
 
Cadmium 
 
Infertile Japanese women; 54 cases, 74 controls 
No association with urinary cadmium levels 
  
 
Hoffman et al, 
2007(17) 
 
PBBs 
PCBs 
 
Study of women inadvertantly exposed to PBBs in 
1973.  Self-reported endometriosis. No association 
between PBB exposure and disease. 
 
Porpora et al, 
2006(18) 
 
PCBs 
 
Case-control study of nulliparous Italian women 
N=40 cases, 40 w/ benign gynecological conditions 
Association between blood levels and disease 
 
Quaranta et al, 
2006(19) 
 
PCBs 
DDE 
 
Laparoscopy patients 
N=10 endometriosis, 8 controls 
Significantly higher serum PCB and DDE levels 
with endometriosis 
 
Heilier et al, 
2006(20) 
 
Cadmium 
Lead 
 
N= 119 cases, 25 controls 
Lower lead levels in cases 
 
Reddy et al, 
2006(21) 
 
Phthalates 
 
Laparoscopy patients 
N=49 endometriosis, 59 controls 
Significantly higher concentrations of phthalate 
esters with endometriosis and correlations with 
disease severity 
 
 
Louis et al, 
2005(22) 
 
 
PCBs 
 
Laparoscopy patients 
N=32 endometriosis, 50 controls 
Significantly elevated OR for 3rd tertile PCBs 
 
Heilier et al, 
2005(23) 
 
Dioxins 
PCBs 
 
Case-control study; N=25 cases, 21 controls 
Increased risk association for dioxin and total 
dioxin-like PCB serum concentrations 
 
Tsukino et al, 
2005(24) 
 
Dioxins 
PCBs 
 
Infertile Japanese women; N= 58 cases, 81 controls 
No significant associations 
 
Heilier et al, 
2004(25) 
 
Cadmium 
 
Case-control study; N= 29  
No difference in serum cadmium concentration 
 
 
De Felip et al, 
2004(26) 
 
Dioxins 
PCBs 
 
Case-control study of 22 Italian, 18 Belgian women 
No significant difference between cases and 
controls 
 
Corbellis et al, 
2003(27) 
 
Phthalates 
 
Laparoscopy patients 
N=59 endometriosis, 24 age-matched controls 
Significantly higher plasma DEHP with disease 
 
Fierens et al, 
2003(28) 
 
Dioxins 
PCBs 
 
Population-based studies of exposed Belgian 
women 
No significant associations 
 
Eskenazi et al, 
2002(29) 
 
TCDD 
 
Population-based historical cohort study; 19 
endometriosis, 277 nondiseased 
No significant association 
 
Pauwels et al, 
2001(30) 
 
Dioxins 
PCBs 
 
Infertile women N= 34 cases, 29 controls 
No significant associations 
 
Taskinen et al, 
1999(31) 
 
Formaldehyde 
Organic 
solvents 
 
Occupationally exposed women 
Suggestion of association 
 
Lebel et al, 
1998(32) 
 
PCBs 
Chlorinated 
pesticides 
 
Case-control study of laparoscopy patients 
N=86 endometriosis, 70 controls 
No significant differences 
 
   
Mayani et al, 
1997(33) 
TCDD Infertile women undergoing larparoscopy; N=44 
endometriosis, 35 age-matched controls 
 
 
Gerhard and 
Runnebaum, 
1992(34) 
 
PCBs 
 
Women with hormonal irregularities 
PCB values significantly higher in women with 
endometriosis    
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